BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
The company's lead drug Azelaprag, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials.BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering.
专注于开发代谢性疾病治疗方法的生物年龄实验室公司，提交了SEC备案文件，计划在首次公开募股中最多筹集10000万美元。
The company was founded in 2015 and plans to list on the Nasdaq under the symbol BIOA. BioAge Labs filed confidentially on May 31, 2024.
该公司成立于2015年，计划在纳斯达克上市，股票代码为BIOA。BioAge Labs于2024年5月31日进行了保密文件备案。
Goldman Sachs, Morgan Stanley, Jefferies, and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
高盛、摩根士丹利、Jefferies和Citi是该交易的联席承销商。没有披露定价条款。
The company's lead drug Azelaprag, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials.
公司的首席药物Azelaprag是一种口服小分子，已在八项一期临床试验中的265名患者中得到了良好的耐受性。
Also Read: Newly Listed Obesity Player Fractyl Health Shares Encouraging Preclinical Data.
此外，也有报道称：新上市的肥胖治疗公司Fractyl Health分享了令人鼓舞的临床前数据。
In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while restoring healthy body composition and improving muscle function.
在临床前肥胖模型中，azelaprag表现出能够将胰高血糖素样肽-1受体（GLP-1R）激动剂引起的减重效果超过一倍，并恢复健康的体组成和改善肌肉功能。
The company plans to assess azelaprag's potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 trials.
该公司计划在两个二期临床试验中评估azelaprag与GLP-1R激动剂联合使用时在减重方面带来的显著改善。
The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound by Eli Lilly And Co (NYSE:LLY), with topline results anticipated in the third quarter of 2025.
正在进行的STRIDES临床试验将评估azelaprag与Eli Lilly And Co（纽交所代码：LLY）推出的Zepbound（tirzepatide）的联合使用，预计在2025年第三季度发布最终结果。
The second Phase 2 trial will assess azelaprag in combination with semaglutide, marketed as Wegovy by Novo Nordisk A/S (NYSE:NVO), with initiation expected in the first half of 2025.
第二阶段2试验将评估与诺和诺德A/S (纽交所:NVO)的Wegovy（semaglutide的市场名称）联合使用的azelaprag，预计在2025年上半年开始
BioAge also intends to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion.
BioAge还计划在2025年上半年启动azelaprag单药的胰岛素敏感性概念验证试验，以支持潜在的适应症扩展
The company is also developing orally available small-molecule brain-penetrant NLRP3 inhibitors for diseases driven by neuroinflammation and anticipates submitting an Investigational New Drug application for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 trial in the first half of 2026.
该公司还正在开发可口服、小分子、能穿透血脑屏障的神经炎症相关脑炎原环受体3（NLRP3）抑制剂，预计在2025年下半年提交一项NLRP3抑制剂的新药申请，并在2026年上半年启动第一阶段试验（如果通过初审）
In February, BioAge Labs completed a Series D financing round of $170 million led by Sofinnova Investments.
BioAge Labs在2月份完成了一轮17000万美元的D轮融资，由Sofinnova Investments领投
- Alibaba's Taobao and Tmall Launch New Tech Venture, Eyeing Global Market Growth.
- 阿里巴巴的淘宝和天猫推出新的科技创业公司，瞄准全球市场增长
Photo by Vidmir Rais via Pixabay
来自Pixabay的Vidmir Rais摄影作品
